公开(公告)号：US11866787B2

公开(公告)日：2024-01-09

申请号：US17018845

申请日：2020-09-11

申请人： The Johns Hopkins University

发明人： Jun Luo ,  Emmanuel S. Antonarakis ,  Changxue Lu

IPC分类号： C12Q1/68 ,  C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： Methods of the present disclosure provide for detection of mutations and splice variants of the androgen receptor using a non-invasive approach, RNAseq, for examining circulating tumor cells.

公开(公告)号：US20170275673A1

公开(公告)日：2017-09-28

申请号：US15505882

申请日：2015-08-25

申请人： The Johns Hopkins University

发明人： Jun Luo ,  Emmanuel S. Antonarakis ,  Changxue Lu ,  Willian Isaacs

IPC分类号： C12Q1/68 ,  A61K45/06 ,  A61K31/00 ,  A61K39/00

CPC分类号： C12Q1/686 ,  A61K31/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/6056 ,  A61K2300/00 ,  C12Q1/6853 ,  C12Q2521/107 ,  C12Q2539/103 ,  C12Q2545/114

摘要： Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with prostate cancer. Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with castration-resistant prostate cancer wherein such biological molecules and biomarkers comprise androgen-receptor splice variants that can be used to develop effective therapeutic regimens for prostate cancer patients. Disclosed herein are methods of using biological molecules and biomarkers related to androgen-receptor splice variants for assessing therapeutic resistance to drugs such as enzalutamide and abiraterone.

公开(公告)号：US11345956B2

公开(公告)日：2022-05-31

申请号：US15505882

申请日：2015-08-25

申请人： The Johns Hopkins University

发明人： Jun Luo ,  Emmanuel S. Antonarakis ,  Changxue Lu ,  William Isaacs

IPC分类号： C12Q1/68 ,  C12Q1/686 ,  A61K39/00 ,  A61K31/00 ,  A61K45/06 ,  C12Q1/6853

摘要： Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with prostate cancer. Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with castration-resistant prostate cancer wherein such biological molecules and biomarkers comprise androgen-receptor splice variants that can be used to develop effective therapeutic regimens for prostate cancer patients. Disclosed herein are methods of using biological molecules and biomarkers related to androgen-receptor splice variants for assessing therapeutic resistance to drugs such as enzalutamide and abiraterone.

公开(公告)号：US20210032706A1

公开(公告)日：2021-02-04

申请号：US17018845

申请日：2020-09-11

申请人： The Johns Hopkins University

发明人： Jun Luo ,  Emmanuel S. Antonarakis ,  Changxue Lu

IPC分类号： C12Q1/6886

摘要： Methods of the present disclosure provide for detection of mutations and splice variants of the androgen receptor using a non-invasive approach, RNAseq, for examining circulating tumor cells.